Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 31Neoplasms 6Breast Neoplasms 6Prostatic Neoplasms, Castration-Resistant 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Metastatic Castration Resistant Prostate Cancer 4Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Prostate Adenocarcinoma 2Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Thrombocytosis 1Solid Tumours 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pharmacokinetics of MDV3100 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

enzalutamide 1dactolisib 1NVP-BKM120 1Injections 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Castration-resistant Prostate Cancer × enzalutamide × Clear all
NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡